I. Tcherepanova

发表

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

The Immunosuppressive Properties of the HIV Vpr Protein Are Linked to a Single Highly Conserved Residue, R90

J. Routy, Brad L. Lackford, D. Calderhead, 2009, PloS one.

Dendritic cell subsets generated from CD34+ hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses.

H. Ueno, J. Banchereau, A. Palucka, 2004, Journal of immunological methods.

Priming of a Novel Subset of CD28+ Rapidly Expanding High-Avidity Effector Memory CTL by Post Maturation Electroporation-CD40L Dendritic Cells Is IL-12 Dependent1

M. Debenedette, D. Calderhead, I. Tcherepanova, 2008, The Journal of Immunology.

IL-12 Dependent Electroporation-CD 40 L Dendritic Cells Is CTL by Post Maturation Expanding High-Avidity Effector Memory Rapidly + Priming of a Novel Subset of CD 28

M. Debenedette, D. Calderhead, I. Tcherepanova, 2008 .

Evaluation of a microfluidics-based platform and slab electrophoresis for determination of size, integrity and quantification of in vitro transcribed RNA used as a component in therapeutic drug manufacturing.

J. G. Slagter-Jäger, I. Tcherepanova, C. Nicolette, 2012, Journal of pharmaceutical and biomedical analysis.

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

R. Figlin, W. Miller, V. Master, 2015, Journal of Immunotherapy for Cancer.

The Past, Present, and Future of Non-Viral CAR T Cells

A. Biondi, Chiara F. Magnani, A. Moretti, 2022, Frontiers in Immunology.

Cytokine Maturation Followed by CD40L mRNA Electroporation Results in a Clinically Relevant Dendritic Cell Product Capable of Inducing a Potent Proinflammatory CTL Response

M. Debenedette, D. Calderhead, I. Tcherepanova, 2008, Journal of immunotherapy.

SAT0193 Results of a randomized placebo controlled phase ia study of AGS-009, a humanized anti-interferon-α monoclonal antibody in subjects with systemic lupus erythematosus

M. Sale, I. Tcherepanova, C. Nicolette, 2013 .

A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice.

C. Fathman, R. Creusot, I. Tcherepanova, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Impact of Autologous Dendritic Cell–Based Immunotherapy (AGS-004) on B- and T-Cell Subset Changes and Immune Activation in HIV-Infected Patients Receiving Antiretroviral Therapy

J. Routy, M. Debenedette, M. Jenabian, 2013, Journal of acquired immune deficiency syndromes.

Effect of number and position of EBNA-1 binding sites in Epstein-Barr virus oriP on the sites of initiation, barrier formation, and termination of replication

C. Schildkraut, T. Platt, I. Tcherepanova, 1993, Journal of virology.

Topical Application of Soluble CD83 Induces IDO-Mediated Immune Modulation, Increases Foxp3+ T Cells, and Prolongs Allogeneic Corneal Graft Survival

L. Boon, U. Grohmann, M. T. Pallotta, 2013, The Journal of Immunology.

Allogeneic Corneal Graft Survival T Cells , and Prolongs + Increases Foxp 3 IDO-Mediated Immune Modulation , Topical Application of Soluble CD 83 Induces

L. Boon, U. Grohmann, M. T. Pallotta, 2013 .

Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes

M. Debenedette, A. Steinkasserer, A. Mellor, 2017, The Journal of Immunology.

Binding to the TLR 4 / MD2 Complex on Soluble CD 83 Inhibits T Cell Activation by

M. Debenedette, A. Steinkasserer, H. Lemos, 2017 .

Soluble CD83 ameliorates experimental colitis in mice

A. Pommer, T. Mak, M. Debenedette, 2014, Mucosal Immunology.

Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.

J. Routy, R. Sékaly, B. Yassine-Diab, 2010, Clinical immunology.

Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response

M. Debenedette, A. Raney, I. Tcherepanova, 2013, Molecular therapy. Nucleic acids.

Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products.

C A Nicolette, D Healey, I Tcherepanova, 2007, Vaccine.

An improved RNA amplification procedure results in increased yield of autologous RNA transfected dendritic cell-based vaccine.

J. Freedman, I. Tcherepanova, T. Monesmith, 2005, Biochimica et biophysica acta.

Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC).

R. Figlin, V. Master, M. Debenedette, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion

D. Calderhead, I. Tcherepanova, C. Nicolette, 2008, BMC Molecular Biology.

Potency of Mature CD40L RNA Electroporated Dendritic Cells Correlates With IL-12 Secretion by Tracking Multifunctional CD8+/CD28+ Cytotoxic T-cell Responses In Vitro

M. Debenedette, Mark A. DeBenedette, David M. Calderhead, 2011, Journal of immunotherapy.

Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

J. Routy, D. Margolis, D. Asmuth, 2016, Journal of acquired immune deficiency syndromes.

Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.

J. Coffin, D. Margolis, N. Archin, 2017, AIDS research and human retroviruses.

Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma

W. Lowrance, R. Figlin, C. Wood, 2020, Clinical Cancer Research.

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection

M. Hudgens, D. Margolis, R. Gorelick, 2020, Scientific Reports.

Multiplex RT-PCR Amplification of HIV Genes to Create a Completely Autologous DC-Based Immunotherapy for the Treatment of HIV Infection

D. Calderhead, Aijing Z. Starr, I. Tcherepanova, 2008, PloS one.

Title Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA : A randomized , double-blind , placebo-controlled clinical trial Permalink

J. Routy, D. Margolis, D. Asmuth, 2022 .

Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib.

R. Figlin, V. Master, M. Debenedette, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.